Hereditary hepatic and systemic amyloidosis caused by a new deletion/insertion mutation in the apolipoprotein AI gene.

dc.contributor.author
Booth, David R.
dc.contributor.author
Tan, Si-Yen
dc.contributor.author
Booth, Sussanne E.
dc.contributor.author
Tennent, Glenys A.
dc.contributor.author
Hutchinson, Winston L.
dc.contributor.author
Hsuan, J. Justin
dc.contributor.author
Totty, Nicholas F.
dc.contributor.author
Truong, Oanh
dc.contributor.author
Soutar, Anne K.
dc.contributor.author
Hawkins, Philip N.
dc.contributor.author
Bruguera i Cortada, Miquel, 1942-
dc.contributor.author
Caballeria Rovira, Joan
dc.contributor.author
Solé, Manel
dc.contributor.author
Campistol Plana, Josep M.
dc.contributor.author
Pepys, Mark B.
dc.date.issued
2009-05-15T08:23:06Z
dc.date.issued
2009-05-15T08:23:06Z
dc.date.issued
1996
dc.identifier
0021-9738
dc.identifier
https://hdl.handle.net/2445/8305
dc.identifier
122436
dc.identifier
8675681
dc.description.abstract
We report a Spanish family with autosomal-dominant non-neuropathic hereditary amyloidosis with a unique hepatic presentation and death from liver failure, usually by the sixth decade. The disease is caused by a previously unreported deletion/insertion mutation in exon 4 of the apolipoprotein AI (apoAI) gene encoding loss of residues 60-71 of normal mature apoAI and insertion at that position of two new residues, ValThr. Affected individuals are heterozygous for this mutation and have both normal apoAI and variant molecules bearing one extra positive charge, as predicted from the DNA sequence. The amyloid fibrils are composed exclusively of NH2-terminal fragments of the variant, ending mainly at positions corresponding to residues 83 and 92 in the mature wild-type sequence. Amyloid fibrils derived from the other three known amyloidogenic apoAI variants are also composed of similar NH2-terminal fragments. All known amyloidogenic apoAI variants carry one extra positive charge in this region, suggesting that it may be responsible for their enhanced amyloidogenicity. In addition to causing a new phenotype, this is the first deletion mutation to be described in association with hereditary amyloidosis and it significantly extends the value of the apoAI model for investigation of molecular mechanisms of amyloid fibrillogenesis.
dc.format
8 p.
dc.format
application/pdf
dc.language
eng
dc.publisher
American Society for Clinical Investigation
dc.relation
Reproducció del document publicat a http://dx.doi.org/10.1172/JCI118725
dc.relation
Journal of Clinical Investigation, 1996, vol. 97, núm. 12, p. 2714¿2721.
dc.relation
http://dx.doi.org/10.1172/JCI118725
dc.rights
(c) The American Society for Clinical Investigation, 1996
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (Medicina)
dc.subject
Amiloïdosi
dc.subject
Proteïnes
dc.subject
Fetge
dc.subject
Genètica molecular
dc.subject
Amyloidosis
dc.subject
Apolipoprotein AI
dc.subject
Gene
dc.subject
Liver
dc.subject
Mutation
dc.title
Hereditary hepatic and systemic amyloidosis caused by a new deletion/insertion mutation in the apolipoprotein AI gene.
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)